Last reviewed · How we verify

TACE regimen — Competitive Intelligence Brief

TACE regimen (TACE regimen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Locoregional chemotherapy/embolization procedure. Area: Oncology.

phase 3 Locoregional chemotherapy/embolization procedure Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TACE regimen (TACE regimen) — Sun Yat-sen University. TACE (transarterial chemoembolization) is a locoregional therapy that delivers chemotherapy directly to hepatocellular carcinoma tumors via the hepatic artery while simultaneously blocking blood supply to the tumor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TACE regimen TARGET TACE regimen Sun Yat-sen University phase 3 Locoregional chemotherapy/embolization procedure

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Locoregional chemotherapy/embolization procedure class)

  1. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TACE regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/tace-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: